...
ipa-img

Immunoprecise Antibodies Ltd, Common Stock

IPA

NMQ

$0.4001

+$0.02

(5.26%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$12.10M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
439.20K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.27
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.32 L
$2.6 H
$0.4001

About Immunoprecise Antibodies Ltd, Common Stock

ImmunoPrecise Antibodies Ltd., a biotechnology company, leverages multi-omics modeling and artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; peptide production for subsequent antibody discovery campaign; B cell select platform, which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. In addition, it provides phage display, a custom immune library; CAR development, an adaptable antibody, which allows the inclusion of functional data early in the screening funnel; antibody sequencing; and assay development. Further, it offers a profiling toolset for antibody lead candidates; and in vitro analytical tools for the study of quality attributes. Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody chimerization for cloning and production of antibody domain; Eurofins preclinical services; hybrid service model designed to reduce time and risk with custom applications; breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts; and protein manufacturing services. The company is headquartered in Victoria, Canada. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameIPASectorS&P500
1-Week Return9.05%-2.82%0.15%
1-Month Return-14.87%-4.22%1.78%
3-Month Return-37.48%-9.52%8.7%
6-Month Return-61.9%-3.45%12.24%
1-Year Return-63.95%5.62%30.9%
3-Year Return-92.09%3.8%30.19%
5-Year Return-78.77%39.68%91.72%
10-Year Return27.02%105.02%203.2%

Financials

Apr '20Apr '21Apr '22Apr '23Apr '245YR TREND
Total Revenue14.06M17.91M19.36M20.66M24.52M[{"date":"2020-04-30","value":57.34,"profit":true},{"date":"2021-04-30","value":73.06,"profit":true},{"date":"2022-04-30","value":78.98,"profit":true},{"date":"2023-04-30","value":84.29,"profit":true},{"date":"2024-04-30","value":100,"profit":true}]
Cost of Revenue6.02M6.37M8.38M9.10M12.46M[{"date":"2020-04-30","value":48.33,"profit":true},{"date":"2021-04-30","value":51.14,"profit":true},{"date":"2022-04-30","value":67.24,"profit":true},{"date":"2023-04-30","value":73.02,"profit":true},{"date":"2024-04-30","value":100,"profit":true}]
Gross Profit8.03M11.54M10.98M11.56M12.05M[{"date":"2020-04-30","value":66.66,"profit":true},{"date":"2021-04-30","value":95.73,"profit":true},{"date":"2022-04-30","value":91.12,"profit":true},{"date":"2023-04-30","value":95.93,"profit":true},{"date":"2024-04-30","value":100,"profit":true}]
Gross Margin57.15%64.41%56.72%55.95%49.16%[{"date":"2020-04-30","value":88.72,"profit":true},{"date":"2021-04-30","value":100,"profit":true},{"date":"2022-04-30","value":88.05,"profit":true},{"date":"2023-04-30","value":86.87,"profit":true},{"date":"2024-04-30","value":76.32,"profit":true}]
Operating Expenses12.08M15.71M27.15M39.78M12.05M[{"date":"2020-04-30","value":30.37,"profit":true},{"date":"2021-04-30","value":39.5,"profit":true},{"date":"2022-04-30","value":68.25,"profit":true},{"date":"2023-04-30","value":100,"profit":true},{"date":"2024-04-30","value":30.3,"profit":true}]
Operating Income(4.09M)(6.65M)(15.78M)(26.09M)(13.76M)[{"date":"2020-04-30","value":-409400000,"profit":false},{"date":"2021-04-30","value":-665300000,"profit":false},{"date":"2022-04-30","value":-1578100000,"profit":false},{"date":"2023-04-30","value":-2609100000,"profit":false},{"date":"2024-04-30","value":-1376200000,"profit":false}]
Total Non-Operating Income/Expense(346.81K)(2.66M)(207.00K)(1.90M)(14.94M)[{"date":"2020-04-30","value":-34680900,"profit":false},{"date":"2021-04-30","value":-265900000,"profit":false},{"date":"2022-04-30","value":-20700000,"profit":false},{"date":"2023-04-30","value":-190100000,"profit":false},{"date":"2024-04-30","value":-1493700000,"profit":false}]
Pre-Tax Income(5.29M)(6.00M)(15.85M)(27.75M)(28.70M)[{"date":"2020-04-30","value":-529315400,"profit":false},{"date":"2021-04-30","value":-599500000,"profit":false},{"date":"2022-04-30","value":-1584800000,"profit":false},{"date":"2023-04-30","value":-2775200000,"profit":false},{"date":"2024-04-30","value":-2870300000,"profit":false}]
Income Taxes(345.73K)1.34M861.00K(1.19M)(1.53M)[{"date":"2020-04-30","value":-25.7,"profit":false},{"date":"2021-04-30","value":100,"profit":true},{"date":"2022-04-30","value":64.01,"profit":true},{"date":"2023-04-30","value":-88.62,"profit":false},{"date":"2024-04-30","value":-113.46,"profit":false}]
Income After Taxes(4.95M)(7.34M)(16.71M)(26.56M)(27.18M)[{"date":"2020-04-30","value":-494742600,"profit":false},{"date":"2021-04-30","value":-734000000,"profit":false},{"date":"2022-04-30","value":-1670900000,"profit":false},{"date":"2023-04-30","value":-2656000000,"profit":false},{"date":"2024-04-30","value":-2717700000,"profit":false}]
Income From Continuous Operations(4.95M)(7.34M)(16.71M)(26.56M)(27.18M)[{"date":"2020-04-30","value":-494742600,"profit":false},{"date":"2021-04-30","value":-734000000,"profit":false},{"date":"2022-04-30","value":-1670900000,"profit":false},{"date":"2023-04-30","value":-2656000000,"profit":false},{"date":"2024-04-30","value":-2717700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-04-30","value":"-","profit":true},{"date":"2021-04-30","value":"-","profit":true},{"date":"2022-04-30","value":"-","profit":true},{"date":"2023-04-30","value":"-","profit":true},{"date":"2024-04-30","value":"-","profit":true}]
Net Income(4.95M)(7.34M)(16.71M)(26.56M)(27.18M)[{"date":"2020-04-30","value":-494742600,"profit":false},{"date":"2021-04-30","value":-734000000,"profit":false},{"date":"2022-04-30","value":-1670900000,"profit":false},{"date":"2023-04-30","value":-2656000000,"profit":false},{"date":"2024-04-30","value":-2717700000,"profit":false}]
EPS (Diluted)(0.46)(0.40)(0.82)(1.08)(0.46)[{"date":"2020-04-30","value":-45.99,"profit":false},{"date":"2021-04-30","value":-39.71,"profit":false},{"date":"2022-04-30","value":-81.67,"profit":false},{"date":"2023-04-30","value":-108,"profit":false},{"date":"2024-04-30","value":-46,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

IPA
Cash Ratio 0.28
Current Ratio 1.01
Quick Ratio 0.85

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

IPA
ROA (LTM) -13.45%
ROE (LTM) -64.04%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

IPA
Debt Ratio Lower is generally better. Negative is bad. 0.46
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.54

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

IPA
Trailing PE NM
Forward PE NM
P/S (TTM) 0.48
P/B 0.50
Price/FCF NM
EV/R 1.21
EV/Ebitda NM

FAQs

What is Immunoprecise Antibodies Ltd share price today?

Immunoprecise Antibodies Ltd (IPA) share price today is $0.4001

Can Indians buy Immunoprecise Antibodies Ltd shares?

Yes, Indians can buy shares of Immunoprecise Antibodies Ltd (IPA) on Vested. To buy Immunoprecise Antibodies Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IPA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Immunoprecise Antibodies Ltd be purchased?

Yes, you can purchase fractional shares of Immunoprecise Antibodies Ltd (IPA) via the Vested app. You can start investing in Immunoprecise Antibodies Ltd (IPA) with a minimum investment of $1.

How to invest in Immunoprecise Antibodies Ltd shares from India?

You can invest in shares of Immunoprecise Antibodies Ltd (IPA) via Vested in three simple steps:

  • Click on Sign Up or Invest in IPA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Immunoprecise Antibodies Ltd shares
What is Immunoprecise Antibodies Ltd 52-week high and low stock price?

The 52-week high price of Immunoprecise Antibodies Ltd (IPA) is $2.6. The 52-week low price of Immunoprecise Antibodies Ltd (IPA) is $0.32.

What is Immunoprecise Antibodies Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Immunoprecise Antibodies Ltd (IPA) is

What is Immunoprecise Antibodies Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Immunoprecise Antibodies Ltd (IPA) is 0.50

What is Immunoprecise Antibodies Ltd dividend yield?

The dividend yield of Immunoprecise Antibodies Ltd (IPA) is 0.00%

What is the Market Cap of Immunoprecise Antibodies Ltd?

The market capitalization of Immunoprecise Antibodies Ltd (IPA) is $12.10M

What is Immunoprecise Antibodies Ltd’s stock symbol?

The stock symbol (or ticker) of Immunoprecise Antibodies Ltd is IPA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top